MedDRA preferred term

Recalled product administered: adverse event reports recording this term

8,692 reports to FDA record it, 2010–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

8,692
reports recording the term: 0% of all reports; 1,347
reports, 12 months to June 2026: 2,064 in the 12 months before; 22.5%
marked serious by the reporter: 57.4% across all reports; 1.3%
record death among outcomes, as reported: 9.1% across all reports

8,692 reports in FDA's adverse event database record the MedDRA term "Recalled product administered": 0% of all reports received between July 2010 and June 2026. Coders pick the term that best matches the reporter's description.

1,347 reports recorded it in the 12 months to June 2026, down 35% from 2,064 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 22.5% are marked serious, 1.3% include death among the outcomes and 5.6% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Ramipril, Lisinopril and Bicillin L-A. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Ramipril	Angiotensin converting enzyme inhibitor	1,026	2.8%
Lisinopril	Angiotensin converting enzyme inhibitor	737	1.7%
Bicillin L-A	Penicillin-class antibacterial	571	64.1%
Chantix	Partial cholinergic nicotinic agonist	376	0.5%
Levothyroxine sodium	l-Thyroxine	375	2.6%
Hizentra	Human immunoglobulin G	253	1.1%
Valsartan	Angiotensin 2 receptor blocker	240	1.4%
Zilretta	—	226	27%
Quinapril	Angiotensin converting enzyme inhibitor	202	16.4%
Sertraline hydrochloride	Serotonin reuptake inhibitor	142	1.3%
Zonisamide	Anti-epileptic agent	134	2.7%
Relpax	Serotonin-1b and Serotonin-1d receptor agonist	114	3.4%
Lisdexamfetamine	Central nervous system stimulant	110	8.9%
NP Thyroid	l-Thyroxine	106	14.1%
Ceftriaxone	Cephalosporin antibacterial	89	0.5%
Alprazolam	Benzodiazepine	83	0.2%
Kogenate Fs	—	79	3.9%
Privigen	Human immunoglobulin G	75	0.9%
Fluticasone propionate	Corticosteroid	71	1%
Niacin	—	69	4.2%
Desloratadine	Histamine-1 receptor antagonist	62	2.3%
Losartan potassium	Angiotensin 2 receptor blocker	58	0.9%
Ozurdex	Corticosteroid	57	2.3%
Testosterone cypionate	Androgen	56	1.8%
Liraglutide	GLP-1 receptor agonist	54	3.7%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Angiotensin converting enzyme inhibitor	1,971	1.9%	0%
Penicillin-class antibacterial	571	0.9%	0%
l-Thyroxine	498	1%	0.3%
Angiotensin 2 receptor blocker	422	0.2%	0%
Partial cholinergic nicotinic agonist	378	0.5%	0.3%
Human immunoglobulin G	365	0.5%	0%
Anti-epileptic agent	217	0.1%	0%
Corticosteroid	194	0%	0%
Cephalosporin antibacterial	143	0.3%	0%
Serotonin reuptake inhibitor	142	0.1%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.5%41

2 to 111.2%107

12 to 170.8%66

18 to 446.9%603

45 to 6411.7%1,013

65 to 746.3%546

75 and over4%349

Age not given68.6%5,967

Patient sex

Female32.9%2,861

Male18%1,561

Not given49.1%4,270

Grey bar: all 20,646,523 reports in the database. 98.4% of these reports give the United States as the country.

Questions about "Recalled product administered"

What does "Recalled product administered" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record recalled product administered?

8,692 reports through June 2026 (0% of all reports), 1,347 of them in the latest 12 months.

Which drugs appear most often in these reports?

Ramipril (1,026), Lisinopril (737), Bicillin L-A (571), Chantix (376) and Levothyroxine sodium (375). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.